AI in drug discovery
AI in drug discovery is the application of artificial intelligence, machine learning, and deep learning across the pharmaceutical pipeline to identify drug targets, design new molecules, predict protein…
Healthcare AI
Explore Healthcare AI through related topics and the articles other pages reference most.
Explore articles
Browse subtopics: AI for Science
Articles that also belong to these categories. Counts cover all of Healthcare AI.
All articles (62)AI Companies (30)Drug Discovery (14)Robotics (8)AI for Science (7)AI Models (6)Google DeepMind (5)AI Benchmarks (4)Google (4)Large Language Models (4)Open Source AI (4)Chinese AI (3)OpenAI (3)AI Agents (2)AI Hardware (2)AI Tools & Products (2)Artificial Intelligence (2)Computer Vision (2)Deep Learning (2)Enterprise AI (2)Natural Language Processing (2)AI History (1)AI Policy & Regulation (1)AI Research (1)Autonomous Vehicles (1)ChatGPT (1)Conversational AI (1)Developer Tools (1)Machine Learning (1)Medical imaging (1)Microsoft (1)Mixture of Experts (1)NVIDIA (1)Robotics Companies (1)Transformer Models (1)Voice AI (1)
Showing 1-7 of 7 articles
AlphaGenome
AlphaGenome is a unified deep learning model developed by Google DeepMind that predicts thousands of functional genomic properties from raw DNA sequences.
AlphaGenome Atlas
AlphaGenome Atlas is a precomputed catalog of molecular-effect predictions for genetic variants, released by Google DeepMind on September 8, 2026.
AlphaMissense
AlphaMissense is a machine learning model from Google DeepMind that predicts whether a missense variant, a single amino-acid substitution in a protein, is likely to cause disease.
Brain-Computer Interface
A brain-computer interface (BCI), also called a brain-machine interface, is a system that measures activity in the nervous system and translates it into commands for an external device, bypassing muscles and…
Rentosertib
Rentosertib is an investigational oral small-molecule inhibitor of TNIK (TRAF2- and NCK-interacting kinase) developed by Insilico Medicine for idiopathic pulmonary fibrosis (IPF)
Virtual Biology Initiative
The Virtual Biology Initiative is a five-year, $500 million research program announced on April 29, 2026 by Biohub, the science organization of the Chan Zuckerberg Initiative (CZI).